GEN Edge - GEN - Genetic Engineering and Biotechnology News

StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics

StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia

UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs

Artificial Intelligence

Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

StockWatch: Novartis Loses More than Market Value After Phase III Failure

StockWatch: Novartis Loses More than Market Value After Phase III Failure

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems

With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

CDMOs Expand and Build for Future Growth

CDMOs Expand and Build for Future Growth

BMS Chooses Houston for $2.3B Manufacturing Facility

BMS Chooses Houston for $2.3B Manufacturing Facility

StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss

StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss